Copper Ophthalmic Cross-Linking Agents for Keratoconus Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions like keratoconus, such as corneal thinning and biomechanical weakness, are limited and costly, with procedures like Corneal Collagen Cross-link (CXL) therapy being cost-prohibitive and invasive, while surgical options carry significant risks.
Innovation Solution
A copper-containing cross-linking agent is administered topically to increase lysyl oxidase activity, enhancing corneal collagen cross-linking and biomechanical strength, thereby stabilizing the cornea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If Corneal Collagen Cross-link (CXL) therapy is used to treat keratoconus, then corneal strength is improved, but the treatment becomes invasive and cost-prohibitive
Solution Approach 1:
The patent replaces the mechanical/physical CXL procedure (invasive corneal treatment requiring epithelial removal and UV light exposure) with a biochemical approach using copper-containing ophthalmic compositions that activate lysyl oxidase enzyme to promote natural collagen cross-linking, thereby eliminating surgical invasiveness while maintaining therapeutic effectiveness
Solution Approach 2:
The patent changes the treatment parameter from external physical energy (UV light in CXL) to biochemical catalysis (copper ions activating lysyl oxidase), transforming the treatment mechanism from mechanical/physical intervention to biological process enhancement, which reduces invasiveness and cost
2Strength
If surgical options are used to treat keratoconus, then corneal strength is improved, but significant risks are introduced
Solution Approach 1:
The patent substitutes surgical mechanical intervention with topical biochemical treatment, replacing knife-based procedures and tissue removal with copper-containing eye drops that activate natural enzymatic cross-linking, thereby eliminating surgical risks while achieving corneal strengthening
Solution Approach 2:
The patent enables the cornea to perform self-repair by activating its own lysyl oxidase enzyme system through copper supplementation, allowing the tissue to naturally form cross-links without external surgical intervention, thus avoiding surgical risks entirely
3Reliability
If existing treatments are used for corneal thinning, then some therapeutic effect is achieved, but the treatments are limited and costly
Solution Approach 1:
The patent creates a multi-functional treatment approach where copper-containing ophthalmic compositions simultaneously address corneal thinning, biomechanical weakness, and irregular astigmatism by promoting collagen cross-linking, offering a versatile solution that overcomes the limitations of disease-specific treatments
Solution Approach 2:
The patent replaces costly and limited existing treatments with a biochemical mechanism using copper ions to activate lysyl oxidase, providing a cost-effective and versatile therapy that can be administered topically and addresses multiple corneal pathologies simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method improves corneal strength and reduces diopter measurements, providing a non-invasive and cost-effective alternative to current treatments, potentially delaying or halting the progression of keratoconus.
Implementation Method 1
A copper-containing cross-linking agent is administered topically to increase lysyl oxidase activity, enhancing corneal collagen cross-linking and biomechanical strength
Data Source
AI summary
An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.